LEGN LEGEND BIOTECH CORP

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.

Investors and other interested parties may join the live webcast through this or visit Legend Biotech’s website under .

About Legend Biotech

With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at and follow us on and .

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

PRESS CONTACT:

Mary Ann Ondish

Tel: (914) 552-4625



EN
19/05/2025

Underlying

LEGNLEGEND BIOTECH CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEGEND BIOTECH CORP

 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Event During the 2025 American Society...

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinici...

7h / 24m 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlight...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biot...

May 13, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on First Quarter 2025 ...

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this . A replay of the webcast and...

April 29, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and R...

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial run...

March 11, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on Fourth Quarter and ...

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call ...

February 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch